Search
Search Constraints
You searched for: Author/Creator Poder, Airi Journal VaccineLimit your search
- Poder, Airi [remove] 5
- 615.372 5
- Vaccines -- Periodicals 5
- HZ herpes zoster -- RZV adjuvanted recombinant zoster vaccine -- VZV varicella-zoster virus -- gE VZV glycoprotein E -- AE adverse event -- SAE serious AE -- pIMD potential immune-mediated disease -- D day -- M month -- Y year -- YOA years of age -- ZOE-50/70 the pivotal RZV efficacy trials in adults ≥50/≥70 YOA -- MedDRA medical dictionary for regulatory activities -- SOC system organ class -- PT preferred term -- CI confidence interval -- RR relative risk -- AML acute myeloid leukemia 1
- Herpes zoster -- Adjuvanted recombinant zoster vaccine -- 23-Valent pneumococcal polysaccharide vaccine -- Immune response -- Safety 1
- Recombinant zoster vaccine -- Efficacy -- Herpes zoster -- Sex -- Region -- Geographic ancestry/ethnicity 1
- VZV varicella-zoster virus -- HZ herpes zoster -- PHN postherpetic neuralgia -- CDC United States Centers for Disease Control and Prevention -- YOA years of age -- ZVL zoster vaccine live -- RZV adjuvanted recombinant zoster vaccine -- PPSV23 23-valent pneumococcal polysaccharide vaccine -- PCV13 13-valent pneumococcal conjugate vaccine -- IDP invasive pneumococcal disease -- gE glycoprotein E -- M month -- GMC geometric mean concentration -- GMT geometric mean titer -- ELISA enzyme-linked immunosorbent assay -- MOPA multiplex opsonophagocytic assay -- VRR vaccine response rate -- (S)AE (serious) adverse event -- pIMD potential immune-mediated disease -- CI confidence interval -- LL/UL lower/upper limit -- TVC total vaccinate cohort -- ATP according-to-protocol 1
- VZV varicella-zoster virus -- gE glycoprotein E -- HZ herpes zoster -- HZ/su HZ subunit vaccine containing 50 µg VZV gE and AS01B Adjuvant System -- YOA years of age -- VE vaccine efficacy -- Gr group -- ELISA enzyme-linked immunosorbent assay -- mIU milli-International Units -- GMC geometric mean concentration -- VRR vaccine response rate -- CI confidence interval -- LL lower limit -- AE adverse event -- SAE serious AE -- pIMDs potential immune-mediated diseases -- TVC total vaccinated cohort -- ATP according-to-protocol 1
- Varicella-zoster virus -- Herpes zoster -- Shingles -- Vaccine -- HZ/su -- Immunogenicity 1
- Varicella-zoster virus -- Vaccine -- Safety -- Reactogenicity 1